FINWIRES · TerminalLIVE
FINWIRES

$LLY

93 stories mentioning LLY

Every FINWIRES story that references LLY, newest first.

Insider Trading

Eli Lilly Insider Sold Shares Worth $2,876,925, According to a Recent SEC Filing

Ilya Yuffa, Executive Vice President and President, Lilly USA and Global Customer Capabilities, Eli Lilly and Company, on June 10, 2026, sold 2,500 shares in Eli Lilly (LLY) for $2,876,925. Following the Form 4 filing with the SEC, Yuffa has control over a total of 29,804 common shares of the company, with 29,804 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/59478/000182600126000006/xslF345X05/wk-form4_1781209410.xml

$LLY
Sectors

Sector Update: Healthcare Stocks Higher Late Afternoon

Healthcare stocks rose late Thursday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding 1.4%.The iShares Biotechnology ETF (IBB) climbed 3%.In corporate news, Adial Pharmaceuticals (ADIL) shares surged 45% after it said Thursday it has acquired Azora Therapeutics, a biopharmaceutical company developing treatments for serious inflammatory diseases.Novartis (NVS) shares gained 4.2% after the company said a phase 1/2 trial of its experimental treatment del-brax met both primary and key secondary endpoints in people with facioscapulohumeral muscular dystrophy.Novo Nordisk (NVO) won approval from UK regulators for its Wegovy pill, a daily oral version of semaglutide, for weight management in adults with obesity or overweight and a weight-related condition. Novo shares rose 2.8%.Some employers in the US intend to drop coverage of GLP-1 medications for weight loss in 2027 amid the increasing popularity of Novo Nordisk's Wegovy and Eli Lilly's (LLY) Zepbound and Foundayo, Reuters reported, citing the Business Group on Health, a policy research group for large employers. Lilly shares were up 2.9%.

$ADIL$LLY$NVO$NVS
Sectors

Sector Update: Healthcare Stocks Rise Thursday Afternoon

Healthcare stocks rose Thursday afternoon, with the NYSE Healthcare Index adding 0.6% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 0.5%.The iShares Biotechnology ETF (IBB) climbed 1.9%.In corporate news, Novartis (NVS) shares gained 2.9% after the company said a phase 1/2 trial of its experimental treatment del-brax met both primary and key secondary endpoints in people with facioscapulohumeral muscular dystrophy.Novo Nordisk (NVO) won approval from UK regulators for its Wegovy pill, a daily oral version of semaglutide, for weight management in adults with obesity or overweight and a weight-related condition. Novo shares rose 1.2%.Some employers in the US intend to drop coverage of GLP-1 medications for weight loss in 2027 amid the increasing popularity of Novo Nordisk's Wegovy and Eli Lilly's (LLY) Zepbound and Foundayo, Reuters reported, citing the Business Group on Health, a policy research group for large employers. Lilly shares were up 1.5%.

$LLY$NVO$NVS
Wire

Market Chatter: Some US Employers Plan to Drop GLP-1 Coverage for Obesity in 2027

Some employers in the US intend to drop coverage of GLP-1 medications for weight loss in 2027 amid the increasing popularity of Novo Nordisk's (NVO) Wegovy and Eli Lilly's (LLY) Zepbound and Foundayo, Reuters reported Thursday, citing the Business Group on Health, a policy research group for large employers.Around 10% of employers who now cover GLP-1 drugs for weight-loss said they are planning to drop that coverage next year, the report said, citing the policy research group.Novo Nordisk and Eli Lilly didn't immediately reply to requests for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $43.51, Change: $+0.72, Percent Change: +1.68%

$LLY$NVO
Wire

Some US Employers Plan to Drop GLP-1 Coverage for Obesity in 2027, Reuters Reports

Some US Employers Plan to Drop GLP-1 Coverage for Obesity in 2027, Reuters Reports

$LLY$NVO
Sectors

Sector Update: Healthcare Stocks Rise Late Afternoon

Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index rising 1.6% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 1.2%.The iShares Biotechnology ETF (IBB) added 1.2%.In corporate news, GSK (GSK) said it signed a definitive agreement Tuesday to acquire Nuvalent (NUVL) for $10.6 billion in cash. GSK shares rose 1%, and Nuvalent surged 39%.Brookdale Senior Living (BKD) has reported May occupancy data in line with bullish comments by the company's management at a recent event and ahead of levels implied in RBC's model for Q2, RBC Capital Markets said in a note. Brookdale shares jumped past 8%.PTC Therapeutics (PTCT) shares climbed 3.3% after Citigroup upgraded the company's stock to buy and raised its price target to $108.Eli Lilly (LLY) signed a collaboration and licensing deal worth over $1 billion with AlzeCure Pharma for global rights to its investigative candidate for Alzheimer's disease. Lilly shares were down 0.4%.

$BKD$GSK$LLY$NUVL$PTCT
Sectors

Sector Update: Healthcare Stocks Rise Tuesday Afternoon

Healthcare stocks were higher Tuesday afternoon, with the NYSE Healthcare Index rising 1.1% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 0.8%.The iShares Biotechnology ETF (IBB) rose 0.2%.In corporate news, GSK (GSK) said it signed a definitive agreement Tuesday to acquire Nuvalent (NUVL) for $10.6 billion in cash. GSK shares rose 0.9%, and Nuvalent surged 39%.Eli Lilly (LLY) entered into a collaboration and licensing agreement worth over $1 billion with Swedish pharmaceutical company AlzeCure Pharma for global rights to its investigative candidate for Alzheimer's disease. Lilly shares were down 0.5%.NeuroSense Therapeutics (NRSN) shares added 1% after it said Tuesday that it has been issued a patent by the Japan Patent Office for PrimeC, its lead drug candidate to treat amyotrophic lateral sclerosis.

$GSK$LLY$NRSN$NUVL
Wire

Jefferies Adjusts Eli Lilly Price Target to $1,350 From $1,330, Maintains Buy Rating

Jefferies Adjusts Eli Lilly Price Target to $1,350 From $1,330, Maintains Buy Rating

$LLY
Eli Lilly Signs Alzheimer's Licensing Deal Worth Over $1 Billion With AlzeCure
US Markets

Eli Lilly Signs Alzheimer's Licensing Deal Worth Over $1 Billion With AlzeCure

Eli Lilly (LLY) shares were up early Tuesday as the drugmaker entered into a collaboration and licensing agreement worth over $1 billion with Swedish pharmaceutical company AlzeCure Pharma for global rights to its investigative candidate for Alzheimer's disease.Under the terms of the deal, Lilly will pay $10 million upfront to AlzeCure, which will also be eligible for mid-single-digit royalties on sales, the Swedish company said. Development and commercial milestone payments could push the total value of the transaction above $1 billion, excluding royalties.Lilly's stock increased 1.1% in the most recent premarket activity.AlzeCure is developing Alzstatin ACD680, a gamma-secretase modulator, to reduce the production of the harmful amyloid-beta protein, which forms the building blocks of the amyloid plaques found in the brains of Alzheimer's patients, the company said."The Alzstatin compounds are hoped to be used to counteract re-accumulation of harmful amyloid in the brain," AlzeCure Chief Executive Martin Jonsson said in a statement. "In the long term, these compounds may also serve as a preventive treatment to prevent the development of Alzheimer's disease."The deal requires approval from regulatory authorities in Sweden, according to AlzeCure."The agreement with Lilly is an important milestone for AlzeCure and Alzstatin," Jonsson said.Lilly didn't immediately respond to a request for comment by.Lilly recently announced that its experimental obesity drug retatrutide delivered significant weight loss in two clinical studies and showed "meaningful" improvements in knee osteoarthritis pain and sleep apnea. The company also announced that overweight or obese women taking the highest dose of its obesity pill Foundayo, or orforglipron, lost weight across all stages of menopause in late-stage trials.

$LLY
Sectors

Sector Update: Healthcare Stocks Decline Late Afternoon

Healthcare stocks were lower late Monday afternoon, with the NYSE Healthcare Index shedding 0.4% and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.1%.The iShares Biotechnology ETF (IBB) fell 0.9%.In corporate news, Johnson & Johnson (JNJ) eased 0.3% after the firm said it has agreed to buy cancer drug developer Firefly Bio for $1 billion in cash to strengthen its oncology portfolio.Incyte (INCY) agreed to acquire Vega Therapeutics, a subsidiary of Star Therapeutics, in a deal worth up to $2 billion, expanding its hematology portfolio into bleeding disorders. Shares fell 1%.Eli Lilly (LLY) shares rose 1.6% after the drugmaker said its experimental obesity drug retatrutide delivered significant weight loss in two clinical studies and also showed "meaningful" improvements in knee osteoarthritis pain and sleep apnea.Tango Therapeutics (TNGX) surged 51% after the firm said initial results from its phase 1/2 trial of vopimetostat plus Revolution Medicines' daraxonrasib showed a six-month progression-free survival rate of 90% in people with pancreatic cancer.

$INCY$JNJ$LLY$TNGX
Sectors

Sector Update: Healthcare Stocks Decline Monday Afternoon

Healthcare stocks were lower Monday afternoon, with the NYSE Healthcare Index shedding 0.4% and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.3%.The iShares Biotechnology ETF (IBB) fell 1%.In corporate news, Johnson & Johnson (JNJ) decreased 0.8% after the company said Monday that it has agreed to acquire cancer drug developer Firefly Bio for $1 billion in cash to strengthen its oncology portfolio.Incyte (INCY) agreed to acquire Vega Therapeutics, a subsidiary of Star Therapeutics, in a deal worth up to $2 billion, expanding its hematology portfolio into bleeding disorders. Shares fell 3%.Eli Lilly (LLY) shares rose 2.2% after the drugmaker said its experimental obesity drug retatrutide delivered significant weight loss in two clinical studies and also showed "meaningful" improvements in knee osteoarthritis pain and sleep apnea.

$INCY$JNJ$LLY
Sectors

Sector Update: Healthcare

Healthcare stocks eased Monday afternoon, with the NYSE Healthcare Index down 0.3% and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.1%.The iShares Biotechnology ETF (IBB) was down 0.7%.In corporate news, Eli Lilly (LLY) shares rose 2.4% after the drugmaker said its experimental obesity drug retatrutide delivered significant weight loss in two clinical studies and showed "meaningful" improvements in knee osteoarthritis pain and sleep apnea.

$LLY
Wire

Top Midday Stories: US Weighs Financial Stakes in AI Firms; Google, Nvidia Turn to Intel as TSMC Struggles With Demand

All three major US stock indexes were up in late-morning trading Monday, after Iran's Ministry of Foreign Affairs said its military has ceased its strikes against Israel, though they could resume if Israeli operations in Lebanon continue.The US government is considering taking a financial stake in artificial intelligence companies, with President Donald Trump planning to meet with executives next week, news outlets reported late Friday, citing the president's comments aboard Air Force One.In company news, Alphabet's (GOOG, GOOGL) Google and Nvidia (NVDA) have turned to Intel (INTC) as a backup manufacturer for their most advanced processors as Taiwan Semiconductor Manufacturing (TSM) struggles to meet overwhelming demand, The Information reported Monday, citing four people with direct knowledge of the discussions. Google has placed an order for over 3 million Tensor Processing Units from Intel in 2028, the report said, citing two of the people. Nvidia hasn't placed an order with Intel, but its evaluating whether Intel technology can be used to make a processor that combines four graphics chips into a single unit, two of the people reportedly told The Information. Shares of Alphabet's Class C and Class A shares were both down 1.2% around midday. Nvidia shares were up 1%. Intel shares were up 12%, while TSM shares were up 3.5%.Eli Lilly (LLY) said Sunday that overweight or obese female patients reduced their body weight throughout all menopausal phases while using the maximum dose of its Foundayo medication in two medical trials. The first trial showed that pre-menopausal, perimenopausal and post-menopausal individuals dropped a maximum of 28 pounds, 30.4 pounds, and 28.2 pounds over 72 weeks, the company said. During the second study focusing on subjects with type 2 diabetes, patients in the same three physiological stages shed up to 23.4 pounds, 18.5 pounds, and 27.8 pounds, the company said. Separately, the company reported Saturday that additional phase 3 data showed that its investigational molecule retatrutide achieved substantial weight loss with meaningful improvements in obesity-related conditions, including knee osteoarthritis pain, moderate-to-severe obstructive sleep apnea, and type 2 diabetes. Eli Lilly shares were up 2.6%.Amazon (AMZN) said Monday it signed a multibillion-dollar deal with Corning (GLW) to supply optical fiber, cable and connectivity products for its growing US data center network. Amazon shares were down 0.1%, while Corning shares were up 6.3%.SpaceX (SPCX) has attracted about $150 billion in investor demand for its initial public offering, about twice the $75 billion it aims to raise, Reuters reported Sunday, citing people familiar with the matter.Tango Therapeutics (TNGX) said Monday that initial results from its phase 1/2 trial of vopimetostat, an investigational PRMT5 inhibitor, in combination with Revolution Medicines inhibitor daraxonrasib showed a six-month progression-free survival rate of 90% in patients with pancreatic cancer. Tango shares were up 47%.Campbell's (CPB) reported fiscal Q3 adjusted earnings Monday of $0.50 per diluted share, down from $0.73 a year earlier but above the FactSet consensus analyst estimate of $0.48. Fiscal Q3 net sales were $2.37 billion, down from $2.48 billion a year ago and below the FactSet consensus of $2.38 billion. Campbell's shares were down 1.2%.Price: $207.86, Change: $+2.76, Percent Change: +1.35%

$AMZN$CPB$GLW$GOOG$GOOGL$INTC$LLY$NVDA$TNGX$TSM
Commodities

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday as Chip Stocks Rebound

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.4%, and the actively traded Invesco QQQ Trust (QQQ) advanced 0.9% in Monday's premarket activity, as semiconductor shares rebound from Friday's selloff.US stock futures were also higher, with S&P 500 Index futures up 0.8%, Dow Jones Industrial Average futures advancing 0.3%, and Nasdaq futures gaining 1.4% before the start of regular trading.The New York Fed's inflation expectations report for May will be released at 11 am ET.In premarket action, bitcoin was up by 3.8%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was 0.4% higher, Ether ETF (EETH) advanced 6.8%, and Bitcoin & Ether Market Cap Weight ETF (BETH) retreated by 0.01%.Power Play:IndustrialThe State Street Industrial Select Sector SPDR ETF (XLI) advanced 0.6%, while the Vanguard Industrials Index Fund (VIS) was up 0.8% and the iShares US Industrials ETF (IYJ) was inactive.Graham (GHM) stock was down more than 7% before the opening bell after the company reported lower fiscal Q4 adjusted net income.Winners and Losers:TechnologyThe State Street Technology Select Sector SPDR ETF (XLK) advanced by 1.8%, and the iShares US Technology ETF (IYW) was 1.8% higher, while the iShares Expanded Tech Sector ETF (IGM) was up 1.8%. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) increased by 3.8%, while the iShares Semiconductor ETF (SOXX) rose by 4.1%.Nvidia (NVDA) shares were up more than 2% in premarket activity after dropping by 6.2% on Friday. The company will expand artificial intelligence infrastructure in South Korea, beginning with a 55-megawatt deployment at Naver's GAK Sejong data center. The chipmaker also closed a multi-year deal with SK hynix to design future generations of artificial intelligence memory hardware.ConsumerThe State Street Consumer Staples Select Sector SPDR ETF (XLP) was down 0.2% and the Vanguard Consumer Staples Index Fund ETF Shares (VDC) was up 0.8%. The iShares US Consumer Staples ETF (IYK) advanced by 0.1%. The State Street Consumer Discretionary Select Sector SPDR ETF (XLY) gained 0.8%. The VanEck Retail ETF (RTH) was inactive, while the State Street SPDR S&P Retail ETF (XRT) rose by 1%.Ingredion (INGR) shares were up 0.8% pre-bell after the company said it has launched an all-cash tender offer to acquire Tate & Lyle, valuing the specialty ingredients company at about 3.7 billion British pounds ($5 billion).HealthcareThe State Street Health Care Select Sector SPDR ETF (XLV) advanced 0.2%, the Vanguard Health Care Index Fund (VHT) was down 0.2%, while the iShares US Healthcare ETF (IYH) slipped 0.2%. The iShares Biotechnology ETF (IBB) was 0.2% higher.Eli Lilly (LLY) stock was up more than 1% premarket after the drugmaker said its experimental obesity drug retatrutide delivered significant weight loss in two clinical studies and showed "meaningful" improvements in knee osteoarthritis pain and sleep apnea.FinancialThe State Street Financial Select Sector SPDR ETF (XLF) advanced 0.1%. Direxion Daily Financial Bull 3X Shares (FAS) was up 0.4%, while its bearish counterpart, Direxion Daily Financial Bear 3X Shares (FAZ), was 0.4% lower.Blackstone (BX) shares were up 0.4% pre-bell after closing Friday with a 2.7% fall. The Financial Times reported the company is preparing to offload more than $2 billion in private fund stakes through a structured bond deal.EnergyThe iShares US Energy ETF (IYE) was up 0.7%, while the State Street Energy Select Sector SPDR ETF (XLE) was up by 0.7%.Eni (E) stock was up nearly 1% before the opening bell, following a 1.1% decline in the prior trading session. Petronas and Eni said they have launched a new 50/50 joint venture called Searah that will combine businesses across Indonesia and Malaysia.CommoditiesFront-month US West Texas Intermediate crude oil gained by 0.9% to $91.33 per barrel on the New York Mercantile Exchange. Natural gas was down 2.9% to $3.13 per 1 million British Thermal Units. The United States Oil Fund (USO) advanced by 2%, while the United States Natural Gas Fund (UNG) was 2.4% lower.Gold futures for July retreated by 0.3% to $4,354.00 an ounce on the Comex. Silver futures declined by 0.7% to $68.60 an ounce. SPDR Gold Shares (GLD) was up by 0.2%, and the iShares Silver Trust (SLV) increased by 0.5%.

Dow JonesNasdaq CompositeS&P 500$BETH$BITO$BX$E$EEM$EETH$EXI$FAS$FAZ$GHM$GLD$IBB$IGM$IGV$INGR$IPK$IVV$IWM$IYE$IYH$IYJ$IYK$IYW$LLY$NVDA$PMR$QQQ$RTH$SLV$SOXX$SPY$UNG$USO$VDC$VHT$VIS$XLE$XLF$XLI$XLK$XLP$XLV$XLY$XRT$XSD
Sectors

Sector Update: Healthcare Stocks Steady Pre-Bell Monday

Healthcare stocks were steady pre-bell Monday, with the iShares Biotechnology ETF (IBB) inactive and the State Street Health Care Select Sector SPDR ETF (XLV) up a slight 0.1%.Tango Therapeutics (TNGX) shares were up more than 45% after the company said initial results from its phase 1/2 trial of vopimetostat in combination with Revolution Medicines' inhibitor daraxonrasib showed a six-month progression-free survival rate of 90% in patients with pancreatic cancer.Eli Lilly (LLY) shares were up more than 2% after the company said additional phase 3 data showed that retatrutide achieved substantial weight loss with "meaningful" improvements in obesity-related conditions, including knee osteoarthritis pain, moderate-to-severe obstructive sleep apnea, and type 2 diabetes.Shattuck Labs (STTK) said its phase 1 study of SL-325, a treatment for immune-related disease, showed good safety results and consistent drug performance in healthy volunteers. Shattuck Labs stock was up more than 14% premarket.

$IBB$LLY$STTK$TNGX$XLV
Asia Markets

US Equity Futures Higher Pre-Bell as Trump Tries to Keep Fragile Middle East Ceasefire Intact Amid New Israel-Iran Clashes

US equity futures were edging higher pre-bell Monday as President Donald Trump tried to hold together the fragile Middle East ceasefire after Israel and Iran exchanged attacks over the past few days.Dow Jones Industrial Average futures were 0.3% higher, S&P 500 futures were up 0.8%, and Nasdaq futures were 1.4% higher.In a post on Truth Social, Trump said that Israel and Iran were looking to do an "immediate" ceasefire after the two nations exchanged a series of attacks. Israeli forces on Sunday had launched strikes on Iran-backed Hezbollah forces inside Beirut, Lebanon, and Iran had retaliated with missile attacks. "The Blockade will remain in place, and in full force and effect, until a 'Final Deal' is reached," Trump said.The US imposed a blockade of Iranian ports after Iran barred transit of ships in the Strait of Hormuz.Oracle (ORCL) and Adobe (ADBE) are among the companies scheduled to release quarterly financial results within the week.Oil prices were higher, with front-month global benchmark North Sea Brent crude up 1.8% at $94.74 per barrel and US West Texas Intermediate crude 1.4% higher at $91.82 per barrel.The NY Federal Reserve's June consumer inflation expectations index is scheduled to be released at 11 am ET.In other world markets, Japan's Nikkei closed 3.9% lower, Hong Kong's Hang Seng ended 1.2% lower, and China's Shanghai Composite finished 1.7% lower. Meanwhile, the UK's FTSE 100 was up 0.1%, and Germany's DAX index was 0.3% lower in Europe's early afternoon session.In equities, Nvidia (NVDA) shares rose 2.4% after a Bloomberg report cited company CEO Jensen Huang as saying that a global technology stock selloff was an opportunity to purchase shares at a discount. Eli Lilly (LLY) stock was up 1.7% after the drugmaker said its experimental obesity drug retatrutide delivered significant weight loss in two clinical studies and showed "meaningful" improvements in knee osteoarthritis pain and sleep apnea. Advanced Micro Devices (AMD) stock was up 3.7% after the company said it plans to invest up to 2 billion British Pounds ($2.7 billion) in the UK over the next five years to accelerate artificial intelligence research.On the losing side, Haleon (HLN) shares dropped 1% after the company said it plans to invest about 175 million pounds ($233.1 million) to build a new oral health manufacturing facility in Madhya Pradesh and expand distribution across rural India.

Dow JonesNasdaq CompositeS&P 500$ADBE$AMD$HLN$LLY$NVDA$ORCL
Stocks Mostly Up Pre-Bell as Traders Assess Renewed Middle East Tensions, Await Key Inflation Data
US Markets

Stocks Mostly Up Pre-Bell as Traders Assess Renewed Middle East Tensions, Await Key Inflation Data

The benchmark US stock measures were mostly pointing higher before the opening bell Monday as investors weigh tensions after Iran and Israel exchanged strikes and await key inflation data later this week.The S&P 500 increased 0.4% and the Nasdaq added 0.8% in premarket activity, while the Dow Jones Industrial Average edged down less than 0.1%. The indexes finished Friday's trading session in the red, with the Nasdaq reportedly recording its biggest one-day decline since April 2025.Iran launched a fresh wave of airstrikes against Israel on Monday, Bloomberg News reported. Israel responded with strikes on military targets in western and central Iran, while Iranian state media reported multiple explosions in Tehran, according to Bloomberg.Tensions between the two countries escalated after Iran launched missiles toward Israel over the weekend in retaliation for Israeli strikes on the southern suburbs of Beirut, Lebanon.President Donald Trump told Israeli Prime Minister Benjamin Netanyahu not to retaliate against Iran's attack and allow time for more diplomacy, Axios reported Sunday, citing a senior US official and an Israeli source.An Iranian official involved in the discussions between Washington and Tehran told MS NOW that a peace deal with Trump is "no longer feasible" after the latest exchange of fire.West Texas Intermediate crude oil jumped 3.8% to $94.02 a barrel before the open, while Brent gained 3.6% to $96.43.With no major economic reports scheduled for Monday, traders will turn their attention to the consumer price index for May on Wednesday, followed by data on wholesale prices for the same month on Thursday.On Friday, the Bureau of Labor Statistics reported that total nonfarm payrolls in the US rose by 172,000 in May, nearly double the 88,000 increase expected in a Bloomberg-compiled survey.Treasury yields were trending upwards in premarket action, with the two-year rate rising 0.2 basis points to 4.16% and the 10-year rate inclining 1.8 basis points to 4.55%.Eli Lilly's (LLY) shares advanced 3.9% pre-bell after the drugmaker said its investigational drug for obesity, retatrutide, showed "substantial" weight loss in two clinical studies, as well as "meaningful" improvements in knee osteoarthritis pain and sleep apnea.Oracle (ORCL) and Adobe (ADBE) are scheduled to report their latest financial results later this week. Campbell's (CPB) posts its earnings before the bell Monday.Gold declined 0.9% to $4,325 per troy ounce, while bitcoin climbed 2.9% to $63,118.

Dow JonesNasdaq CompositeS&P 500$ADBE$CPB$LLY$ORCL
Eli Lilly Says Obesity Drug Delivers Significant Weight Loss, Improves Knee Pain and Sleep Apnea in Trials
US Markets

Eli Lilly Says Obesity Drug Delivers Significant Weight Loss, Improves Knee Pain and Sleep Apnea in Trials

Eli Lilly (LLY) shares rose early Monday after the drugmaker said its experimental obesity drug retatrutide delivered significant weight loss in two clinical studies and showed "meaningful" improvements in knee osteoarthritis pain and sleep apnea.The company conducted two phase-three studies of retatrutide, involving 2,876 patients, according to a statement on Saturday.In one of the trials in adults with obesity, participants given the highest 12 mg dose of retatrutide lost an average of 28.3% of their body weight over 80 weeks, according to Lilly. About 65.3% of patients on the high dose achieved a body mass index below 30, no longer meeting the criteria for obesity, the company said.The study also showed that the drug reduced knee osteoarthritis pain by up to 73.1% and cut moderate-to-severe obstructive sleep apnea severity by up to 36.1 events per hour, or 60.6%.The stock gained 4.4% in the most recent premarket activity."Across triumph-1 and transcend-T2D-1, retatrutide delivered substantial weight loss, meaningful (glycated hemoglobin) reduction, and improvements in knee osteoarthritis pain and moderate-to-severe obstructive sleep apnea," Kenneth Custer, executive vice president at Lilly Cardiometabolic Health, said in the statement. "These results highlight retatrutide's potential across the cardiometabolic spectrum."In a second clinical study in adults with type 2 diabetes, retatrutide met its primary endpoint, reducing glycated hemoglobin by up to 2% and body weight by up to 16.8% at 40 weeks.In a separate statement Sunday, the company said overweight or obese women taking the highest dose of its obesity pill Foundayo, or orforglipron, lost weight across all stages of menopause in late-stage trials. In April, the US Food and Drug Administration approved Foundayo for adults with obesity or overweight with weight-related medical problems.

$LLY
Sectors

Sector Update: Healthcare Stocks Climb Late Afternoon

Healthcare stocks were higher late Thursday afternoon, with the NYSE Healthcare Index climbing 3.2% and the State Street Health Care Select Sector SPDR ETF (XLV) rising 3%.The iShares Biotechnology ETF (IBB) added 2.6%.In corporate news, Eli Lilly (LLY) shares gained 4.3% after Ascidian Therapeutics said Lilly will receive exclusive, target-specific rights to Ascidian's RNA exon editing technology for undisclosed kidney disease targets in exchange for up to $1.9 billion under a research partnership and licensing deal.Merck (MRK) shares climbed 5% after it said Thursday it will pay over $50 million to settle more than 200 lawsuits that blame the drugmaker's Gardasil cancer vaccine for causing autoimmune ailments in young women, Bloomberg reported.The US Supreme Court on Thursday ruled that Amarin (AMRN) failed to prove that a generic-drug manufacturer actively induced other companies to infringe upon two of its Vascepa patents after the generic maker received approval for a so-called "skinny-label" version of the drug. Amarin shares fell 4.4%.BofA Securities upgraded UnitedHealth (UNH) to buy from neutral as medical cost trends improve and "supportive" near-term data points form a favorable Q2. UnitedHealth shares rose 5.4%.

$AMRN$LLY$MRK$UNH
Sectors

Sector Update: Healthcare Stocks Gain Thursday Afternoon

Healthcare stocks were higher Thursday afternoon, with the NYSE Healthcare Index climbing 3.2% and the State Street Health Care Select Sector SPDR ETF (XLV) rising 2.8%.The iShares Biotechnology ETF (IBB) added 2.2%.In corporate news, Eli Lilly (LLY) shares climbed 5% after Ascidian Therapeutics said Lilly will receive exclusive, target-specific rights to Ascidian's RNA exon editing technology for undisclosed kidney disease targets in exchange for up to $1.9 billion under a research partnership and licensing deal.Merck (MRK) shares rose 3.9% after it said Thursday it will pay over $50 million to settle more than 200 lawsuits that blame the drugmaker's Gardasil cancer vaccine for causing autoimmune ailments in young women, Bloomberg reported.BofA Securities upgraded UnitedHealth (UNH) to buy from neutral as medical cost trends improvement and "supportive" near-term data points form a favorable Q2. UnitedHealth shares gained 5.2%.

$LLY$MRK$UNH

Showing 1-20 of 93